Eli Lilly's Revenue Soars with Top-Selling Diabetes and Weight Loss Drugs
TL;DR Summary
Eli Lilly's obesity and diabetes drugs Mounjaro and Zepbound generated over $10 billion in Q3, fueling a booming market and a bidding war, with Novo Nordisk planning to acquire Metsera in a deal potentially worth up to $9 billion, highlighting intense competition in the GLP-1 receptor agonist space.
- Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war Yahoo Finance
- Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar CNBC
- Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine statnews.com
- Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance investor.lilly.com
- Eli Lilly Smashes Views On Back Of Mounjaro, Zepbound Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
89%
455 → 48 words
Want the full story? Read the original article
Read on Yahoo Finance